A Phase 1 Study of AZD1775 (MK-1775) Concurrent With Local Radiation Therapy for the Treatment of Newly Diagnosed Children With Diffuse Intrinsic Pontine Gliomas

Study Overview

This phase I trial studies the side effects and the best dose of WEE1 inhibitor MK-1775 when given together with local radiation therapy in treating patients with newly diagnosed diffuse intrinsic pontine gliomas.

Study Description

The purpose of this study is to estimate the maximum tolerated dose (MTD) or recommended phase 2 dose and schedule of the Wee1 inhibitor AZD1775 (MK-1775) (WEE1 inhibitor MK-1775) administered concurrently with radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG); to define and describe the toxicities of AZD1775 (MK-1775) given concurrently with radiation therapy in children with newly diagnosed DIPG; and to characterize the pharmacokinetics of AZD1775 (MK-1775) in children with newly diagnosed DIPG.

Additional Information

Participants will be paid for their participation.

  • IRB Number: 1308763990 (PHO-COG-CROOP-ADVL1217)
  • Research Study Identifier: TX6097
  • Principal Investigator: James Croop, MD, PhD

Recruitment Status


Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

If you need assistance finding a study or if you have any questions, please email: ctsirro@iu.edu or call us at (317) 278-2176